Concepts (176)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Escherichia coli | 13 | 2024 | 986 | 2.950 |
Why?
|
| DNA, Superhelical | 8 | 2024 | 20 | 2.400 |
Why?
|
| Fluoroquinolones | 8 | 2013 | 93 | 2.250 |
Why?
|
| Drug Resistance, Bacterial | 7 | 2018 | 364 | 1.780 |
Why?
|
| Anti-Bacterial Agents | 11 | 2019 | 2420 | 1.610 |
Why?
|
| DNA | 10 | 2024 | 1595 | 1.540 |
Why?
|
| Klebsiella pneumoniae | 3 | 2016 | 74 | 1.400 |
Why?
|
| Ciprofloxacin | 4 | 2018 | 66 | 1.050 |
Why?
|
| Klebsiella Infections | 2 | 2016 | 52 | 1.010 |
Why?
|
| Base Pairing | 1 | 2021 | 42 | 0.750 |
Why?
|
| Endodeoxyribonucleases | 1 | 2021 | 46 | 0.750 |
Why?
|
| Bacterial Proteins | 2 | 2016 | 886 | 0.710 |
Why?
|
| Microbial Sensitivity Tests | 10 | 2019 | 791 | 0.690 |
Why?
|
| DNA Replication | 3 | 2017 | 352 | 0.640 |
Why?
|
| Sugars | 1 | 2019 | 15 | 0.630 |
Why?
|
| Plasmids | 3 | 2016 | 510 | 0.620 |
Why?
|
| Iron | 2 | 2019 | 264 | 0.610 |
Why?
|
| Escherichia coli Infections | 3 | 2012 | 195 | 0.600 |
Why?
|
| Escherichia coli Proteins | 3 | 2024 | 305 | 0.580 |
Why?
|
| DNA Ligases | 1 | 2017 | 17 | 0.570 |
Why?
|
| Acinetobacter baumannii | 2 | 2019 | 36 | 0.560 |
Why?
|
| Orthomyxoviridae | 1 | 2016 | 50 | 0.530 |
Why?
|
| beta-Lactam Resistance | 1 | 2016 | 47 | 0.500 |
Why?
|
| beta-Lactamases | 2 | 2016 | 195 | 0.500 |
Why?
|
| Nucleic Acid Conformation | 6 | 2023 | 184 | 0.480 |
Why?
|
| Bacterial Infections | 1 | 2018 | 310 | 0.480 |
Why?
|
| Virulence Factors | 1 | 2016 | 176 | 0.470 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 2 | 2019 | 134 | 0.470 |
Why?
|
| RNA, Viral | 1 | 2016 | 540 | 0.450 |
Why?
|
| Bacteria | 1 | 2018 | 484 | 0.450 |
Why?
|
| Drug Repositioning | 1 | 2013 | 23 | 0.430 |
Why?
|
| Ofloxacin | 3 | 2012 | 32 | 0.410 |
Why?
|
| Levofloxacin | 3 | 2012 | 45 | 0.400 |
Why?
|
| DNA Topoisomerases, Type II | 2 | 2010 | 22 | 0.400 |
Why?
|
| Pyridones | 1 | 2013 | 111 | 0.400 |
Why?
|
| Norfloxacin | 2 | 2008 | 4 | 0.390 |
Why?
|
| Mutation | 6 | 2019 | 5818 | 0.380 |
Why?
|
| Shear Strength | 1 | 2011 | 17 | 0.370 |
Why?
|
| Genotype | 2 | 2016 | 2556 | 0.360 |
Why?
|
| Respiratory Syncytial Virus, Human | 3 | 2022 | 204 | 0.360 |
Why?
|
| Gene Transfer Techniques | 2 | 2016 | 356 | 0.350 |
Why?
|
| Respiratory Syncytial Virus Vaccines | 2 | 2021 | 67 | 0.350 |
Why?
|
| Transcriptome | 1 | 2016 | 949 | 0.340 |
Why?
|
| DNA, Circular | 3 | 2023 | 16 | 0.330 |
Why?
|
| DNA Gyrase | 3 | 2024 | 22 | 0.330 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 2010 | 158 | 0.330 |
Why?
|
| Models, Molecular | 7 | 2018 | 1069 | 0.290 |
Why?
|
| DNA Topoisomerases | 1 | 2007 | 4 | 0.290 |
Why?
|
| Respiratory Syncytial Virus Infections | 2 | 2021 | 342 | 0.290 |
Why?
|
| Replicon | 1 | 2007 | 6 | 0.280 |
Why?
|
| DNA Nucleotidyltransferases | 1 | 2007 | 19 | 0.280 |
Why?
|
| Proteins | 1 | 2012 | 1035 | 0.270 |
Why?
|
| Models, Chemical | 2 | 2021 | 86 | 0.270 |
Why?
|
| Galactose | 2 | 2019 | 54 | 0.260 |
Why?
|
| Recombination, Genetic | 1 | 2007 | 448 | 0.250 |
Why?
|
| DNA Topoisomerases, Type I | 2 | 2018 | 20 | 0.230 |
Why?
|
| Hydrodynamics | 1 | 2023 | 25 | 0.210 |
Why?
|
| DNA Cleavage | 1 | 2021 | 6 | 0.190 |
Why?
|
| Stress, Mechanical | 1 | 2021 | 167 | 0.180 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2022 | 325 | 0.180 |
Why?
|
| Immunity, Humoral | 1 | 2021 | 70 | 0.170 |
Why?
|
| Genomic Instability | 1 | 2021 | 228 | 0.170 |
Why?
|
| Genetic Vectors | 3 | 2016 | 940 | 0.160 |
Why?
|
| Enterobactin | 1 | 2019 | 2 | 0.160 |
Why?
|
| Klebsiella | 1 | 2019 | 9 | 0.160 |
Why?
|
| Siderophores | 1 | 2019 | 10 | 0.160 |
Why?
|
| Genetic Therapy | 3 | 2016 | 678 | 0.160 |
Why?
|
| Models, Genetic | 1 | 2021 | 759 | 0.150 |
Why?
|
| Sulfolobus solfataricus | 1 | 2018 | 1 | 0.150 |
Why?
|
| DNA, Catenated | 1 | 2018 | 3 | 0.150 |
Why?
|
| Archaeal Proteins | 1 | 2018 | 6 | 0.150 |
Why?
|
| DNA Repair | 1 | 2021 | 584 | 0.150 |
Why?
|
| Genes, Bacterial | 1 | 2019 | 209 | 0.150 |
Why?
|
| Humans | 16 | 2022 | 124149 | 0.140 |
Why?
|
| Enterobacteriaceae | 1 | 2017 | 35 | 0.140 |
Why?
|
| Base Sequence | 4 | 2018 | 3089 | 0.130 |
Why?
|
| Philippines | 1 | 2016 | 23 | 0.130 |
Why?
|
| Antifungal Agents | 1 | 2019 | 288 | 0.130 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2016 | 29 | 0.130 |
Why?
|
| Multilocus Sequence Typing | 1 | 2016 | 56 | 0.130 |
Why?
|
| Carbapenems | 1 | 2016 | 35 | 0.130 |
Why?
|
| Molecular Epidemiology | 1 | 2016 | 155 | 0.120 |
Why?
|
| Genes | 1 | 2016 | 445 | 0.120 |
Why?
|
| Tertiary Care Centers | 1 | 2016 | 236 | 0.120 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2015 | 100 | 0.120 |
Why?
|
| Gene Fusion | 1 | 2014 | 55 | 0.110 |
Why?
|
| Protein Interaction Maps | 1 | 2014 | 78 | 0.110 |
Why?
|
| Luminescent Proteins | 1 | 2014 | 156 | 0.110 |
Why?
|
| DNA Damage | 1 | 2017 | 512 | 0.110 |
Why?
|
| Biosynthetic Pathways | 1 | 2013 | 25 | 0.110 |
Why?
|
| Microbial Viability | 1 | 2013 | 42 | 0.110 |
Why?
|
| Transfection | 2 | 2016 | 1059 | 0.100 |
Why?
|
| Hospitals | 1 | 2016 | 389 | 0.100 |
Why?
|
| RNA, Small Interfering | 2 | 2016 | 659 | 0.100 |
Why?
|
| Drug Resistance, Microbial | 1 | 2013 | 193 | 0.100 |
Why?
|
| Hydrogen Peroxide | 1 | 2013 | 112 | 0.100 |
Why?
|
| DNA Topoisomerase IV | 2 | 2012 | 12 | 0.100 |
Why?
|
| Cells | 1 | 2012 | 27 | 0.100 |
Why?
|
| Oxidative Stress | 1 | 2017 | 798 | 0.100 |
Why?
|
| Lipopolysaccharides | 1 | 2013 | 283 | 0.100 |
Why?
|
| Sonication | 1 | 2011 | 8 | 0.090 |
Why?
|
| DNA, Bacterial | 1 | 2013 | 477 | 0.090 |
Why?
|
| Aged, 80 and over | 2 | 2016 | 6464 | 0.090 |
Why?
|
| Gene Expression | 1 | 2016 | 1559 | 0.090 |
Why?
|
| Nebulizers and Vaporizers | 1 | 2011 | 57 | 0.090 |
Why?
|
| Aerosols | 1 | 2011 | 65 | 0.090 |
Why?
|
| Antibodies, Viral | 3 | 2022 | 1151 | 0.090 |
Why?
|
| Viral Fusion Proteins | 2 | 2021 | 76 | 0.090 |
Why?
|
| Multidrug Resistance-Associated Proteins | 1 | 2010 | 23 | 0.090 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 1 | 2010 | 46 | 0.090 |
Why?
|
| Bacterial Outer Membrane Proteins | 1 | 2010 | 107 | 0.090 |
Why?
|
| Cryoelectron Microscopy | 2 | 2024 | 214 | 0.080 |
Why?
|
| Lipoproteins | 1 | 2010 | 179 | 0.080 |
Why?
|
| Prevalence | 1 | 2016 | 2445 | 0.080 |
Why?
|
| Membrane Transport Proteins | 1 | 2010 | 176 | 0.080 |
Why?
|
| Sentinel Surveillance | 1 | 2008 | 19 | 0.070 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 2007 | 15 | 0.070 |
Why?
|
| Hospitals, County | 1 | 2008 | 23 | 0.070 |
Why?
|
| United States | 2 | 2016 | 10856 | 0.070 |
Why?
|
| Antibodies, Neutralizing | 2 | 2021 | 467 | 0.070 |
Why?
|
| Kinetics | 2 | 2021 | 1321 | 0.070 |
Why?
|
| Texas | 2 | 2021 | 3578 | 0.060 |
Why?
|
| Genes, Reporter | 1 | 2007 | 381 | 0.060 |
Why?
|
| Computer Simulation | 3 | 2017 | 646 | 0.060 |
Why?
|
| Peptides | 2 | 2021 | 792 | 0.060 |
Why?
|
| Aged | 2 | 2016 | 19532 | 0.060 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2013 | 2629 | 0.060 |
Why?
|
| Sex Factors | 1 | 2008 | 1276 | 0.060 |
Why?
|
| Static Electricity | 2 | 2017 | 44 | 0.060 |
Why?
|
| Ultracentrifugation | 1 | 2023 | 20 | 0.050 |
Why?
|
| Phenotype | 1 | 2013 | 4249 | 0.050 |
Why?
|
| Protein Domains | 1 | 2024 | 237 | 0.050 |
Why?
|
| Adult | 4 | 2022 | 29339 | 0.050 |
Why?
|
| Male | 3 | 2016 | 60994 | 0.050 |
Why?
|
| Young Adult | 1 | 2016 | 8990 | 0.050 |
Why?
|
| Gene Expression Regulation | 1 | 2010 | 2516 | 0.050 |
Why?
|
| Female | 3 | 2016 | 66276 | 0.050 |
Why?
|
| Age Factors | 1 | 2008 | 2806 | 0.050 |
Why?
|
| Antibody Formation | 1 | 2021 | 265 | 0.050 |
Why?
|
| Seasons | 1 | 2022 | 310 | 0.040 |
Why?
|
| Mice | 1 | 2016 | 17586 | 0.040 |
Why?
|
| Child, Preschool | 2 | 2021 | 13998 | 0.040 |
Why?
|
| Animals | 2 | 2017 | 34004 | 0.040 |
Why?
|
| DNA, Archaeal | 1 | 2018 | 2 | 0.040 |
Why?
|
| DNA, Concatenated | 1 | 2018 | 5 | 0.040 |
Why?
|
| Torsion, Mechanical | 1 | 2017 | 4 | 0.040 |
Why?
|
| DNA, Single-Stranded | 1 | 2018 | 74 | 0.040 |
Why?
|
| Hot Temperature | 1 | 2018 | 137 | 0.040 |
Why?
|
| Biophysical Phenomena | 1 | 2017 | 39 | 0.040 |
Why?
|
| Electroporation | 1 | 2016 | 32 | 0.030 |
Why?
|
| Cell Line, Tumor | 2 | 2016 | 3331 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2023 | 2863 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2016 | 354 | 0.030 |
Why?
|
| Green Fluorescent Proteins | 1 | 2016 | 390 | 0.030 |
Why?
|
| HeLa Cells | 1 | 2016 | 806 | 0.030 |
Why?
|
| Child | 2 | 2021 | 24356 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2008 | 8189 | 0.030 |
Why?
|
| Fluorescence | 1 | 2014 | 95 | 0.030 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2014 | 135 | 0.030 |
Why?
|
| Infant | 1 | 2008 | 12466 | 0.020 |
Why?
|
| Quinolones | 1 | 2012 | 53 | 0.020 |
Why?
|
| Culture Media | 1 | 2012 | 183 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2012 | 319 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2010 | 316 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2021 | 6121 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 502 | 0.020 |
Why?
|
| Adolescent | 1 | 2008 | 19243 | 0.020 |
Why?
|
| Nucleic Acid Denaturation | 1 | 2009 | 28 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2010 | 619 | 0.020 |
Why?
|
| Biomechanical Phenomena | 1 | 2009 | 225 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2012 | 791 | 0.020 |
Why?
|
| Middle Aged | 1 | 2008 | 26587 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2012 | 1585 | 0.020 |
Why?
|
| Binding Sites | 1 | 2010 | 1293 | 0.020 |
Why?
|
| Protein Binding | 1 | 2010 | 1737 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2010 | 2283 | 0.010 |
Why?
|